<H1>Chapter DOI: 10.1186/s13104-016-2101-8<br/>Cited-By Count: </H1><table border="1" width="30%"><tr><td>Total References</td><td>14</td></tr><tr><td>Springer references</td><td>0</td></tr><tr><td>Non Springer references</td><td>14</td></tr><tr><td>BibStructured Count</td><td width="10%">14</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>10</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267(5197):483&#8211;9.</td><td><a href=http://dx.doi.org/10.1126/science.7824947>10.1126/science.7824947</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350:1023&#8211;35. doi: 10.1056/NEJM200406243502621.</td><td><a href=http://dx.doi.org/10.1056/NEJMra025195>10.1056/NEJMra025195</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibBook</td><td>WHO. WHO HIV drug resistance report 2012. Geneva: World Health Organisation; 2012.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organisation&#8217;s global strategy for prevention and assessment on HIV drug resistance. Antivir Ther. 2008;13(2):1&#8211;13.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, Botes ME, Wellington M, Osiboqun A, Siqaloff KC, Nankya I, Schuurman R, Wit FW, Stevens WS, van Vuqt M, de Wit TF. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011;11:750&#8211;9. doi: 10.1016/S1473-3099(11)70149-9.</td><td><a href=http://dx.doi.org/10.1016/S1473-3099(11)70149-9>10.1016/S1473-3099(11)70149-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Jordan MR, Bennet DE, Winberg MA, Havlir D, Hammer S, Yang C, Morris L, Peeters M, Wensing AM, Parkin N, Nachega JB, Phillips A, De Luca A, Geng E, Calmy A, Raizes E, Sandstrom P, Archibald CP, Perriens J, McClure CM, Hong SY, McMahon JH, Dedes N, Sutherland D, Bertagnolio S. Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004&#8211;2011. Clin Infect Dis. 2012;54(Suppl 4):S245&#8211;9. doi: 10.1093/cid/cis206.</td><td><a href=http://dx.doi.org/10.1093/cid/cis206>10.1093/cid/cis206</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Zhou Z, Wagar N, DeVos JR, Rottinghaus E, Karidia D, Nguyen DB, Bassey O, Ugbena R, Wadonda-Kabondo N, McConnell MS, Zulu I, Chilima B, Nkengasong J, Yang C. Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings. PLoS One. 2011;6(11):e28184. doi: 10.1371/journal.pone.0028184.</td><td><a href=http://dx.doi.org/10.1371/journal.pone.0028184>10.1371/journal.pone.0028184</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Pillay V, Ledwaba J, Hunt G, Rakgotho M, Signh B, Makubalo L, Bennett DE, Morris L. Antiretroviral drug resistance surveillance among drug-naive HIV-1 infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther. 2008;13:101&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Wallis CL, Papathanasopoulos MA, Lakhi S, Karita E, Kamali A, Kaleebu P, Sanders E, Anzala O, Bekker LG, Stevens G, de Wit TF, Stevens W. Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods. 2010;163:505&#8211;8. doi: 10.1016/j.jviromet.2009.11.011.</td><td><a href=http://dx.doi.org/10.1016/j.jviromet.2009.11.011>10.1016/j.jviromet.2009.11.011</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Nwobegahay J, Bessong P, Masebe T, Mavhandu L, Manhaeve C, Ndjeka N, Selabe G. Prevalence of drug-resistant mutations in newly diagnosed drug-na&#239;ve HIV-1 infected individuals in a treatment site in the Waterberg district, Limpopo province. S Afr Med J. 2011;101:335&#8211;7.</td><td><a href=http://dx.doi.org/10.7196/SAMJ.4391>10.7196/SAMJ.4391</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Daar ES, Richman DD. Confronting the emergence of drug resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retrovir. 2005;21:343&#8211;57.</td><td><a href=http://dx.doi.org/10.1089/aid.2005.21.343>10.1089/aid.2005.21.343</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther. 2004;9:695&#8211;702.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Hunt GH, Coovadia A, Abrams AJ, Sherman G, Meyers T, Morris L, et al. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS. 2011;25(12):1461&#8211;9. doi: 10.1097/QAD.0b013e3283492180.</td><td><a href=http://dx.doi.org/10.1097/QAD.0b013e3283492180>10.1097/QAD.0b013e3283492180</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Kambugu A. Pre-ART HIV resistance testing in Africa: are we there yet? Lancet Infect Dis. 2012;12:261. doi: 10.1016/S1473-3099(11)70280-8.</td><td><a href=http://dx.doi.org/10.1016/S1473-3099(11)70280-8>10.1016/S1473-3099(11)70280-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>